Abbassi Ramzi H, Recasens Ariadna, Indurthi Dinesh C, Johns Terrance G, Stringer Brett W, Day Bryan W, Munoz Lenka
Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, John Hopkins Drive, Sydney, New South Wales 2006, Australia.
Oncogenic Signalling Laboratory and Brain Cancer Discovery Collaborative, Telethon Kids Institute, Perth Children's Hospital, 15 Hospital Avenue, Nedlands, Western Australia 6009, Australia.
ACS Pharmacol Transl Sci. 2019 Jul 30;2(6):402-413. doi: 10.1021/acsptsci.9b00045. eCollection 2019 Dec 13.
Sensitivity to microtubule-targeting agents (MTAs) varies among cancers and predicting the response of individual cancer patients to MTAs remains challenging. As microtubules possess vast molecular heterogeneity generated by tubulin isotypes and their post-translational modifications, we questioned whether this heterogeneity can impact MTA sensitivity. We investigated microtubule heterogeneity in 15 glioblastoma cell lines and measured sensitivity of orthogonal MTAs using a per-division growth rate inhibition method that corrects for the confounding effects of variable cell proliferation rates. We found that the tubulin profile is unique for each glioblastoma cell line and that the total α- and β-tubulin levels impact on MTA sensitivity. The baseline levels of α- and β-tubulin were up to 20% lower in cells that were not effectively killed by MTAs. We report that lower α/β-tubulin expression is associated with lack of cell differentiation and increased expression of stemness markers. The dedifferentiated stem-like cells with low α/β-tubulin levels survive MTAs treatment via reversible nonmutational dormancy. Our findings provide novel insights into the relationships between microtubules and MTAs and lay a foundation for better understanding of the sensitivity of cancer cells to MTAs.
不同癌症对微管靶向药物(MTA)的敏感性存在差异,预测个体癌症患者对MTA的反应仍然具有挑战性。由于微管具有由微管蛋白异构体及其翻译后修饰产生的巨大分子异质性,我们质疑这种异质性是否会影响MTA敏感性。我们研究了15种胶质母细胞瘤细胞系中的微管异质性,并使用校正可变细胞增殖率混杂效应的每分裂生长率抑制方法测量了正交MTA的敏感性。我们发现每个胶质母细胞瘤细胞系的微管蛋白谱都是独特的,并且总α-和β-微管蛋白水平会影响MTA敏感性。在未被MTA有效杀死的细胞中,α-和β-微管蛋白的基线水平低至20%。我们报告说,较低的α/β-微管蛋白表达与细胞分化缺乏和干性标志物表达增加有关。具有低α/β-微管蛋白水平的去分化干细胞样细胞通过可逆的非突变性休眠在MTA治疗中存活。我们的研究结果为微管与MTA之间的关系提供了新的见解,并为更好地理解癌细胞对MTA的敏感性奠定了基础。